CMS Star Ratings Recalculation After Clover: Asymmetric Design and 2027 MA Bid Methodology Risk

U.S. District Judge Lisa Godbey Wood ruled on May 27, 2026 that CMS unlawfully included 20 measures in its 2026 Medicare Advantage star ratings, and ordered a recalculation that moved Clover Health's primary PPO contract from 3.5 to 4.5 stars, recovering an estimated $120 million in missed bonus payments. CMS applied the correction in one direction only: upward changes took effect, and the 2026 ratings remain legally deficient as the 2027 bid cycle opens.

Key Takeaways

20 measures held unlawful on two separate theories, one reaching data CMS collected outside its statutory authority and one reaching every measure specification updated through sub-regulatory guidance.
$120 million recovered on one contract moving 3.5 to 4.5 stars, against roughly $12.8 billion of annual quality bonus payments distributed across the program.
The 4.0-star line is a step, not a gradient. QBP moves from 3.5 to 5.0 benchmark points and the rebate return rate from 50% to 65% at the same crossing.
TD Cowen put UnitedHealthcare's gain at roughly $500 million had the Clover rationale applied industry-wide, on an average score moving from 4.11 to 4.27 stars.
Three consecutive plan years of litigation-driven recalculation, following the 2024 revisions that added about $1 billion in bonus payments after the SCAN, Zing Health and Elevance suits.

Why the Number Is That Large on One Contract

Quality bonus payments do not scale smoothly with performance. Plans at 3.5 stars or above receive a QBP equal to 3.5 percentage points on the applicable county benchmark; plans at 4.0 or above receive 5.0 points. At a $1,200 county benchmark, that 1.5-point differential is $18 per member per month of ceiling revenue before any benefit dollar is committed, or $10.8 million a year on 50,000 members.

The rebate steps at the same boundary. Plans below 4.0 return 50% of the benchmark-to-bid spread to members, plans at 4.0 return 65%, and plans at 4.5 or above return 70%.

Medicare Advantage Quality Bonus Payment and Rebate Structure by Star Tier
Star Rating	QBP Benchmark Addition	Rebate Return Rate	Illustrative Annual Swing per 50K Members
Below 3.5 stars	None	50%	Baseline
3.5 stars	+3.5 ppts of county benchmark	50%	+$25.2M vs. sub-3.5
4.0 stars	+5.0 ppts of county benchmark	65%	+$10.8M QBP + $13.5M rebate vs. 3.5 stars
4.5 stars	+5.0 ppts of county benchmark	70%	+$5.4M additional rebate vs. 4.0 stars

A crossing from 3.5 to 4.0 collects both at once. On a $150 benchmark-to-bid spread the rebate moves from $75 to $97.50 per member per month, $1.35 million a year on the same 50,000 members, and the full step from 50% to 65% is worth $22.50 PMPM, roughly $13.5 million annually.

TD Cowen estimated UnitedHealthcare alone would have gained about $500 million in additional quality bonus payments had the Clover rationale been applied uniformly, on an average score moving from 4.11 to 4.27 (Healthcare Dive). Sixteen hundredths of a star. That is what concentration at a step function does, and it is why a plan sitting at 3.5 with a viable claim faces an expected value that clears the cost of federal litigation without much arithmetic.

The Second Legal Theory Is the One That Travels

The court split the 20 measures. The first group of 10, covering medication adherence measures and call center data, failed because CMS collected them outside its statutory authority over MA quality improvement programs.

The second rationale is broader. CMS has routinely updated measure specifications through technical notes and sub-regulatory guidance, adjusting dozens of measures a year without notice-and-comment rulemaking. Because those changes drive payment, the court found they are substantive legal standards requiring rulemaking under the Administrative Procedure Act (Crowell & Moring). The pool of measures updated that way over recent years is much larger than 10.

CareFirst BlueCross BlueShield secured a two-week pause in its parallel suit in June 2026, citing Clover as grounds for CMS to reconsider the methodology more broadly (Becker's Payer Issues). Its contract covers roughly 30,000 beneficiaries in Maryland, and it claims a miscalculation put it at 3.5 rather than 4.0 stars, worth more than $32 million in 2027 quality bonus payments. A pause rather than a dismissal keeps the channel open through the 2027 ratings cycle.

The Star Rating Has Stopped Being a Fixed Bid Input

CMS recalculated 2024 star ratings after the SCAN, Zing Health and Elevance suits, adding roughly $1 billion across the industry, and a second wave followed for 2025. Clover makes 2026 the third consecutive year published ratings were revised after litigation.

In a stable rulemaking environment a published star rating is close to a certainty in the bid, and the only variable is performance risk on the measures. Three consecutive years of successful challenges means the methodology carries its own distribution, independent of anything the plan's clinicians do. A plan at 3.5 stars building 2027 bids now faces two uncorrelated sources of rating uncertainty, and only one of them responds to care management.

The asymmetric correction gives that second source a direction. Upward changes took effect and downward ones did not, so a plan that gains from a recalculation keeps the gain. But if a later ruling or a voluntary CMS action removes measures the plan performed well on, the rating falls with no corresponding protection. A plan whose current rating rests disproportionately on legally vulnerable measures holds one-sided exposure.

That lands hardest on committed benefit budgets. Supplemental dental, vision, hearing and over-the-counter allowances are funded from the rebate, and the rebate steps with the rating. A plan above 4.0 that loses measures it scored well on faces rebate compression inside a plan year where benefits are already contracted to members. Cutting benefits mid-year then concentrates the selection problem: richer benefit packages attract specific chronic condition and care-seeking patterns, and the plan that cannot sustain what it competed on loses the favorable members to competitors that priced more conservatively.

CMS Star Ratings Recalculation After Clover: Asymmetric Design and 2027 MA Bid Methodology Risk

Key Takeaways

Why the Number Is That Large on One Contract

The Second Legal Theory Is the One That Travels

The Star Rating Has Stopped Being a Fixed Bid Input

Further Reading

Sources